We are live on ! Find out more
CRL icon

Charles River Laboratories

676 hedge funds and large institutions have $14.1B invested in Charles River Laboratories in 2024 Q1 according to their latest regulatory filings, with 92 funds opening new positions, 257 increasing their positions, 229 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 46

88% more funds holding in top 10

Funds holding in top 10: 815 (+7)

14% more capital invested

Capital invested by funds: $12.4B → $14.1B (+$1.75B)

12% more repeat investments, than reductions

Existing positions increased: 257 | Existing positions reduced: 229

7% more funds holding

Funds holding: 633676 (+43)

0.47% less ownership

Funds ownership: 102.25%101.79% (-0.47%)

47% less call options, than puts

Call options by funds: $52M | Put options by funds: $98.3M

Holders
676
Holders Change
+43
Holders Change %
+6.79%
% of All Funds
9.74%
Holding in Top 10
15
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+87.5%
% of All Funds
0.22%
New
92
Increased
257
Reduced
229
Closed
46
Calls
$52M
Puts
$98.3M
Net Calls
-$46.4M
Net Calls Change
-$20.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Bessemer Group
276
Bessemer Group
New Jersey
$2.34M +$1.69M +7,095 +457%
CAPTRUST Financial Advisors
277
CAPTRUST Financial Advisors
North Carolina
$2.31M -$578K -2,419 -22%
TFP
278
Tilia Fiduciary Partners
North Carolina
$2.31M +$218K +914 +12%
MA
279
Montag & Associates
Georgia
$2.23M +$1.96M +8,221 New
TAF
280
Tredje AP-fonden
Sweden
$2.2M
SAM
281
Silvercrest Asset Management
New York
$2.2M +$218K +912 +13%
CA
282
CGN Advisors
Kansas
$2.15M +$212K +887 +13%
GWM
283
Geneos Wealth Management
Colorado
$2.07M +$625K +2,617 +52%
VPIM
284
Vanguard Personalized Indexing Management
California
$2.05M +$57.8K +242 +3%
ZB
285
Zions Bancorporation
Utah
$2.03M +$72.4K +303 +4%
State of Tennessee, Department of Treasury
286
State of Tennessee, Department of Treasury
Tennessee
$1.97M -$1.5M -6,273 -46%
CIBC Asset Management
287
CIBC Asset Management
Ontario, Canada
$1.96M +$51.8K +217 +3%
DnB Asset Management
288
DnB Asset Management
Norway
$1.95M +$1.72M +7,187 New
X
289
Xponance
Pennsylvania
$1.94M +$102K +428 +6%
Cerity Partners
290
Cerity Partners
New York
$1.92M +$1.34M +5,629 +383%
IG
291
ING Group
Netherlands
$1.9M +$1.43K +6 +0.1%
DekaBank Deutsche Girozentrale
292
DekaBank Deutsche Girozentrale
Germany
$1.89M -$1.68M -7,038 -50%
Rafferty Asset Management
293
Rafferty Asset Management
New York
$1.88M +$410K +1,717 +33%
SFO
294
Stokes Family Office
Louisiana
$1.88M +$439K +1,840 +36%
AGP
295
Artia Global Partners
Florida
$1.87M
SI
296
Shaker Investments
Ohio
$1.85M +$7.88K +33 +0.5%
PCM
297
Prelude Capital Management
New York
$1.83M +$350K +1,464 +28%
MOACM
298
Mutual of America Capital Management
New York
$1.82M -$33K -138 -2%
FAF
299
Fjarde Ap-fonden
Sweden
$1.77M +$430K +1,800 +38%
PGCM
300
Prescott Group Capital Management
Oklahoma
$1.76M

CRL Hedge Fund Activity: Q1 2024 in Review

676 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2024, worth a combined $14.1B — up 14% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new CRL positions and 46 closed out — a net gain of 46 holders — while 257 added to existing stakes and 229 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $158M. The largest seller was Morgan Stanley, cutting an estimated $122M.

  • 676 institutional investors held Charles River Laboratories (CRL) as of Q1 2024, up from 633 in Q4 2023.
  • Funds reported $14.1B of Charles River Laboratories stock for Q1 2024, up 14% quarter-over-quarter.
  • 92 funds opened new Charles River Laboratories positions in Q1 2024 and 46 closed out, a net change of +46 holders.
  • The largest Charles River Laboratories buyer in Q1 2024 was Marshall Wace, an estimated $158M added.
  • The largest Charles River Laboratories seller in Q1 2024 was Morgan Stanley, an estimated $122M sold.

Based on aggregated 13F filings for Q1 2024.